AC
SNDX icon

Annandale Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Annandale Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,600
Closed -$67K – 154
2023
Q3 		$67K Buy
+4,600
New +$87K 0.02% 128

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Annandale Capital's SNDX Position: Q4 2023 in Review

Annandale Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2023, closing a stake of 4,600 shares — an estimated $67K sold.

Annandale Capital first reported a position in SNDX in Q3 2023 and held it in 1 quarter. The position peaked at $67K in Q3 2023. 177 funds tracked by Wall St. Rank hold SNDX as of Q4 2023.

  • Annandale Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Annandale Capital sold 4,600 Syndax Pharmaceuticals shares in Q4 2023, an estimated $67K.
  • Annandale Capital first reported a position in Syndax Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Annandale Capital's Syndax Pharmaceuticals position peaked at $67K in Q3 2023.
  • 177 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2023.

Based on Annandale Capital's 13F filing for Q4 2023, filed 14 Feb 2024.